Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187®, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 Opposition Proceedings, including any appeal thereto.

Most Recent Presentation
Download Documentation Corporate Presentation

Stock Information
FWP (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Financial Status IndicatorC
Change (%) Stock is Down 0.09 (3.10%)
Data as of 08/14/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: FWP.OQ.  Currently trading at $2.81 with a 52 week high of $9.67 and a 52 week low of $1.64.

Recent NewsMore >>
05/07/18Forward Pharma Appeals the Decision of the Opposition Division to Revoke the EP2801355 Patent
COPENHAGEN, Denmark, May 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today announced the filing of a notice of appeal of the decision of the Opposition Division of the European Patent Office (the “EPO”) that revoked EP2801355 (the “’355 patent”), written reasons for which were received on March 22, 2018. The notice was filed to the Technical Board of Appeal (the “TBA”) of the EPO. “With the notice of appeal filed, we officially initiate t... 
Printer Friendly Version
04/30/18Forward Pharma Reports Full-Year 2017 Financial and Operational Results
COPENHAGEN, Denmark, April 30, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the year ended December 31, 2017. Net income for the year ended December 31, 2017 was $917.1 million, or $2.30 per diluted share, versus net loss of $(33.3) million, or $(0.06) per share for the year ended December 31, 2016. As of December 31, 2017, the Company had $109.6 million in cash and cash equivalents, with no debt outstanding... 
Printer Friendly Version
02/07/18Forward Pharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
COPENHAGEN, Denmark, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will give a corporate update at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY. Dr. Svendsen will present on Thursday, February 15, 2018 at 10:30 AM ET and host one-on-one meetings. Investors and other interested parties may access a live audio webcast of our conference presentati... 
Printer Friendly Version
01/29/18Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent
Forward Pharma Expects to Appeal the Decision Upon Review COPENHAGEN, Denmark, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that the European Patent Office (the “EPO”) has revoked the EP2801355 patent (the “’355 patent”) following the oral hearing in the Opposition Proceedings. The EPO Opposition Division revoked the ’355 patent after considering third-party oppositions from several opponents. The Opposition Division will is... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources